全文获取类型
收费全文 | 24668篇 |
免费 | 1994篇 |
国内免费 | 521篇 |
专业分类
耳鼻咽喉 | 146篇 |
儿科学 | 495篇 |
妇产科学 | 385篇 |
基础医学 | 2146篇 |
口腔科学 | 489篇 |
临床医学 | 2217篇 |
内科学 | 3504篇 |
皮肤病学 | 133篇 |
神经病学 | 1107篇 |
特种医学 | 803篇 |
外国民族医学 | 1篇 |
外科学 | 5902篇 |
综合类 | 3290篇 |
预防医学 | 2380篇 |
眼科学 | 296篇 |
药学 | 1828篇 |
11篇 | |
中国医学 | 973篇 |
肿瘤学 | 1077篇 |
出版年
2024年 | 35篇 |
2023年 | 370篇 |
2022年 | 935篇 |
2021年 | 1024篇 |
2020年 | 912篇 |
2019年 | 762篇 |
2018年 | 944篇 |
2017年 | 769篇 |
2016年 | 870篇 |
2015年 | 852篇 |
2014年 | 1793篇 |
2013年 | 1766篇 |
2012年 | 1477篇 |
2011年 | 1586篇 |
2010年 | 1226篇 |
2009年 | 1337篇 |
2008年 | 1254篇 |
2007年 | 1265篇 |
2006年 | 1120篇 |
2005年 | 972篇 |
2004年 | 768篇 |
2003年 | 608篇 |
2002年 | 553篇 |
2001年 | 482篇 |
2000年 | 479篇 |
1999年 | 419篇 |
1998年 | 331篇 |
1997年 | 298篇 |
1996年 | 274篇 |
1995年 | 253篇 |
1994年 | 233篇 |
1993年 | 193篇 |
1992年 | 142篇 |
1991年 | 138篇 |
1990年 | 100篇 |
1989年 | 91篇 |
1988年 | 90篇 |
1987年 | 65篇 |
1986年 | 59篇 |
1985年 | 59篇 |
1984年 | 51篇 |
1983年 | 25篇 |
1982年 | 40篇 |
1981年 | 16篇 |
1980年 | 27篇 |
1979年 | 25篇 |
1978年 | 26篇 |
1977年 | 13篇 |
1976年 | 9篇 |
1973年 | 8篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
41.
C. M. Gordon E. Binello M. S. LeBoff M. E. Wohl C. J. Rosen A. A. Colin 《Osteoporosis international》2006,17(5):783-790
Introduction Patients with cystic fibrosis (CF) are known to be at risk for early osteoporosis, and the mechanisms that mediate bone loss
are still being delineated. The aim of the present investigation was to investigate if a correlation exists in these patients
between skeletal measurements by dual-energy x-ray absorptiometry (DXA) and two anabolic factors, dehydroepiandrosterone (DHEA)
and insulin-like growth factor I (IGF-I), and proresorptive factors such as the cytokines interleukin-1β, tumor necrosis factor α,
and interleukin-6.
Methods We studied 32 outpatients (18 females; mean age: 26.2 ± 7.9 years) at a tertiary care medical center. The subjects had venous
samples obtained, underwent anthropometric and bone mineral density (BMD) measurements, and completed a health survey. Serum
IGF-I concentrations were below the age-adjusted mean in 78% of the participants, and DHEA sulfate (DHEAS) concentrations
were low in 72%. Serum concentrations of all cytokines were on the low side of normal; nonetheless, there was a modest inverse
correlation between IL-1β and BMD at all sites.
Results In univariate analyses, IGF-I and DHEAS were significant correlates of BMD or bone mineral content. In final multivariate
models controlling for anthropometric and other variables of relevance to bone density, only IGF-I was identified as a significant
independent skeletal predictor. While alterations in DHEAS, IGF-I, and specific cytokines may contribute to skeletal deficits
in patients with CF, of these factors a low IGF-I concentration appears to be most strongly correlated with BMD.
Conclusions These findings may have therapeutic implications for enhancing bone density in these patients. 相似文献
42.
R. P. Heaney T. M. Zizic I. Fogelman W. P. Olszynski P. Geusens C. Kasibhatla N. Alsayed G. Isaia M. W. Davie C. H. Chesnut III 《Osteoporosis international》2002,13(6):501-505
Risedronate treatment reduces the risk of vertebral fracture in women with existing vertebral fractures, but its efficacy
in prevention of the first vertebral fracture in women with osteoporosis but without vertebral fractures has not been determined.
We examined the risk of first vertebral fracture in postmenopausal women who were enrolled in four placebo-controlled clinical
trials of risedronate and who had low lumbar spine bone mineral density (BMD) (mean T-score =–3.3) and no vertebral fractures at baseline. Subjects received risedronate 5 mg (n= 328) or placebo (n= 312) daily for up to 3 years; all subjects were given calcium (1000 mg daily), as well as vitamin D supplementation (up
to 500 IU daily) if baseline serum 25-hydroxyvitamin D levels were low. The incidence of first vertebral fracture was 9.4%
in the women treated with placebo and 2.6% in those treated with risedronate 5 mg (risk reduction of 75%, 95% confidence interval
37% to 90%; P= 0.002). The number of patients who would need to be treated to prevent one new vertebral fracture is 15. When subjects were
stratified by age, similar significant reductions were observed in patients with a mean age of 64 years (risk reduction of
70%, 95% CI 8% to 90%; P= 0.030) and in those with a mean age of 76 years (risk reduction of 80%, 95% CI 7% to 96%; P= 0.024). Risedronate treatment therefore significantly reduces the risk of first vertebral fracture in postmenopausal women
with osteoporosis, with a similar magnitude of effect early and late after the menopause.
Received: 12 September 2001 / Accepted: 11 December 2001 相似文献
43.
Summary This study explores the effects of a calcium-deficient diet on patterns of bone remodeling, and examines regional differences
in the amount of bone lost. Skeletally mature female rabbits (n=6) were fed a calcium-deficient diet (0.10% Ca2+ and 0.50% P) for 14 weeks. A separate group of rabbits (n=4) were fed a maintenance diet (1.2% Ca2+ and 0.45% P). Bone mineral content, serum calcium, and serum phosphorus were measured each week during the experimental period.
Following sacrifice, the L3 vetebra, femoral head, proximal tibial metaphysis, and tibial midshaft were analyzed histomorphometrically. Rabbits had 20%
less vertebral bone after only 14 weeks of a calcium-deficient diet. As in human postmenopausal osteoporosis, bone loss in
calcium-deficient rabbits occurs in the trabecular bone of the lumbar spine before that in the trabecular bone of the lower
extremity. Calcium-deficient diets alone do not lead to increased osteoid volume or thickness. Because bone loss is relatively
rapid and because the pattern of loss is similar in some respects to that found in humans, adult rabbits may provide an attractive
model of calcium deficiency osteoporosis in a skeletally mature mammal in which remodeling is predominant over modeling. 相似文献
44.
Prevention of Bone Loss by Clodronate in Early Postmenopausal Women with Vertebral Osteopenia: A Dose-Finding Study 总被引:1,自引:0,他引:1
M. J. V?lim?ki K. Laitinen K. Laitinen A. Patronen H. Puolijoki H. Puolijoki J. Sepp?nen L. Pylkk?nenand the Probone Study Group 《Osteoporosis international》2002,13(12):937-947
This double-masked, placebo-controlled study was undertaken to determine the efficacy and safety of oral clodronate in the
prevention of bone loss in early postmenopausal women with vertebral osteopenia. Altogether 610 women with a mean age of 53
years were recruited for the study. They were 1–5 years postmenopausal and their lumbar spine bone mineral density (BMD) was
at least 1 standard deviation below the mean of premenopausal women (T-score ≤−1). The subjects were randomized into five study groups to receive either placebo, clodronate 65 mg, 400 mg or 800
mg daily, or intermittent clodronate in 3 month cycles with 400 mg daily for 15 days followed with no treatment for 75 days
for 3 years. One hundred and eighty-seven of 509 women who completed the primary study continued in the extension study of
2 years in which previous placebo users were switched to clodronate 800 mg daily, while previous users of 400 mg or 800 mg
of clodronate used either placebo or 800 mg of clodronate daily. In the primary study clodronate was administered in the evening,
and in the extension 1 h before breakfast on an empty stomach. In the primary study mean changes in lumbar spine BMD were
−3.4% in the placebo group and +0.4% in 800 mg clodronate group [difference between groups at 3 years 3.8% (95% CI 2.7% to
4.9%, p<0.0001)], and in the trochanter area BMD −1.1% in the placebo group, and + 0.4% in the 800 mg clodronate group [difference
between groups at 3 years 1.5% (95% CI 0.05% to 2.9%)]. During the extension study mean changes in lumbar spine BMD were +1.5%
in the clodronate group and −0.2 % in the placebo group [difference between groups 1.7% (CI 0.4% to 3.0%, p = 0.010)] and in trochanter BMD were +2.5% in the clodronate group and no change in the placebo group [difference between
groups 2.1% (CI 0.3% to 3.9%, p = 0.007)]. No statistically significant differences between the placebo and 800 mg clodronate groups were found in the femoral
neck BMD. In the primary study the urinary excretion of type I collagen aminoterminal telopeptide (NTX) decreased by 44% (p<0.0001 compared with placebo) and that of deoxypyridinoline by 18% (p<0.0001) in the clodronate 800 mg group. In the extension study urinary NTX decreased by 51% (p<0.0001) in those who were switched to 800 mg of clodronate and increased by 67% (p<0.0001) in those who stopped using that dose. There was no difference in the frequency of gastrointestinal complaints between
clodronate- and placebo-treated patients in the primary study, but they were more common among women who received clodronate
in the extension phase. Clodronate in daily doses of 400–800 mg caused a slight elevation of aminotransferase levels, usually
within the reference range. In bone biopsies no defect in mineralization was found. In conclusion, clodronate in a daily dose
of 800 mg prevents early postmenopausal bone loss at the sites of the skeleton in which cancellous bone predominates. It effectively
reduces bone resorption and bone turnover rate. Antifracture efficacy of clodronate remains to be established by prospective,
placebo-controlled trials.
Received: 4 March 2002 / Accepted: 9 July 2002 相似文献
45.
Depressed levels of circulating menaquinones in patients with osteoporotic fractures of the spine and femoral neck 总被引:3,自引:0,他引:3
S.J. Hodges M.J. Pilkington T.C.B. Stamp A. Catterall M.J. Shearer L. Bitensky J. Chayen 《BONE》1991,12(6):387-389
Vitamin K1 functions in the conversion of glutamate residues, present in certain bone peptides, into the putatively active γ-carboxyglutamate form. We have shown previously that the circulating levels of vitamin K1 are depressed in osteoporotic patients. However, it is known that menaquinones (vitamin K2:MK) may be more effective than vitamin K1 in this conversion of the inactive to active form of glutamate residues. A procedure for measuring such menaquinones has now demonstrated a marked deficiency of MK-7 and MK-8 in patients with osteoporotic fractures. It is suggested that estimates of circulating levels of K1, MK-7, and MK-8 might provide a biochemical risk marker of osteoporotic fractures. 相似文献
46.
D. M. Reid I. Mackay S. Wilkinson C. Miller D. G. Schuette J. Compston C. Cooper E. Duncan N. Galwey R. Keen B. Langdahl A. McLellan H. Pols A. Uitterlinden J. O’Riordan J. A. H. Wass S. H. Ralston S. T. Bennett 《Osteoporosis international》2006,17(1):125-132
Osteoporosis is a common disease with a strong genetic component characterized by reduced bone mass and an increased risk of fragility fractures. Bone mineral density (BMD) is the most important determinant of osteoporotic fracture risk, but the genes responsible for BMD regulation and fracture are incompletely defined. To enable multi-center studies to examine the genetic influences on BMD there is a requirement to standardize measurements across different manufacturers of bone densitometers, different versions of machines and different normative ranges. This paper describes a method developed to allow near-identical subjects with low age-adjusted BMD (based on Z-scores) to be recruited in 17 centers using 27 different densitometers. Cross-calibration was based on measurements using a European spine phantom circulated to all centers and measured ten times on each individual machine. From theses values an individual exponential curve, based on nominal versus observed BMD, was derived for each machine. As expected, there were large and significant variations in nominal BMD values, not only between scanners from different manufacturers but also between different versions of scanners from the same manufacturer. Hologic scanners tended to underestimate the nominal BMD, while Lunar scanners overestimated the value. Norland scanners gave mixed values over estimating BMD at the lower nominal value (0.5 g/cm2) while underestimating the value at the higher value (1.5 g/cm2). The validity of the exponential equations was tested using hip and spine measurements on 991 non-proband women from a familial osteoporosis study (FAMOS). After cross-calibration there was a considerable reduction in variation between machines. This observation, coupled with the absence of a similar reduction in variation attributable to a linear regression on age, demonstrated the validity of the cross-calibration approach. Use of the cross-calibration curves along with a standard normative range (in the case of this study, the Hologic normative range) allowed age-specific Z-scores to be used as an inclusion criterion in this genetic study, a method that will be useful for other trials where age-specific BMD inclusion criteria are required. 相似文献
47.
Effect of impact exercise on bone mineral density in elderly women with low BMD: a population-based randomized controlled 30-month intervention 总被引:4,自引:3,他引:1
Raija Korpelainen Sirkka Keinänen-Kiukaanniemi Jorma Heikkinen Kalervo Väänänen Juha Korpelainen 《Osteoporosis international》2006,17(1):109-118
Evidence of the effect of exercise on bone loss comes mainly from studies in voluntary postmenopausal women, and no population-based, long-term interventions have been performed. The purpose of this population-based, randomized, controlled trial was to determine the effect of long-term impact exercise on bone mass at various skeletal sites in elderly women with low bone mineral density (BMD) at the radius and hip. Participants ( n =160) were randomly assigned to 30 months either of supervised and home-based impact exercise training or of no intervention. The primary outcome measures were femoral neck, trochanter and total hip BMD, and the secondary outcomes were bone density measures at the radius and calcaneum. Outcomes were assessed at baseline, 12 months and 30 months using blinded operators. The analyses were performed on an intention-to-treat analysis. Mean femoral neck and trochanter BMD decreased in the control group [–1.1%, 95% confidence interval (CI) –0.1% to –2.1% and –1.6%, 95% CI –0.4% to –2.7%], while no change occurred in the exercise group. Mean trochanter BMC decreased more in the control group (–7.7%, 95% CI –9.7% to –5.6% vs. –2.9%, 95% CI –5.3 to –0.9). There were six falls that resulted in fractures in the exercise group and 16 in the control group during the 30-month intervention ( P =0.019). A significant bone loss occurred in both groups at the radius and calcaneum. In multivariate analysis, weight gain was associated with increased BMD and BMC at all femur sites both in the exercise group and in the pooled groups. In conclusion, impact exercise had no effect on BMD, while there was a positive effect on BMC at the trochanter. Exercise may prevent fall-related fractures in elderly women with low bone mass.There was no conflict of interest. 相似文献
48.
目的 建立一种肱骨近端骨密度(BMD)的测量方法,研究肱骨近端BMD与年龄和体质量指数(BMI)的关系,探讨肱骨近端BMD在预报骨质疏松症的敏感性.方法 选择绝经后健康女性志愿者,使用Hologie DELPHI-A双能X射线骨密度仪及本研究设计的肩部定位器和前臂定位器测虽肱骨近端BMD.研究第一部分包括30名忐愿者,每人连续测量右侧肱骨近端BMD 2次,根据测量结果计算短期精密度RMS SD和RMS CV;第二部分包括92名志愿者,记录其年龄、身高、体重,测量右侧肱骨近端BMD,分析肱骨近端BMD与年龄和BMl的相关性.结果 本研究肱骨近端BMD测量方法的短期精密度:RMS SD=0.011 g/cm2,RMS CV=2.4%.本研究92名志愿者平均(60.2±6.4)岁,平均身高(159.5±5.4)cm,平均体质晕(59.4±7.5)kg,平均BMI 23.3±2.7,平均肱骨近端BMD(0.543±0.083)g/cm2,肱骨近端BMD 同年龄呈负相关,同BMI无显著相关.结论 本研究建立了一种测苗肱骨近端BMD的方法;年龄越人肱骨近端BMD越低;由于BMI对BMD的影响会掩盖骨质的丢失,而非负重区域即肱骨近端会最大程度地减少BMI对BMD的影响程度. 相似文献
49.
Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis 总被引:4,自引:0,他引:4
J. S. Hwang S. T. Tu T. S. Yang J. F. Chen C. J. Wang K. S. Tsai 《Osteoporosis international》2006,17(3):373-378
This study compared the clinical efficacy, safety, and tolerability of daily subcutaneous injections of teriparatide and salmon
calcitonin in the treatment of postmenopausal women with established osteoporosis in Taiwan. This 6-month, multicenter, randomized,
controlled study enrolled 63 women with established osteoporosis. They were randomized to receive either teriparatide 20 μg
or calcitonin 100 IU daily in an open-label fashion. Lumber spine, femoral neck, total hip bone mineral density (BMD), and
biochemical markers of bone turnover were measured, and adverse events and tolerability were recorded. The results at 6 months
showed that patients using teriparatide had larger mean increases in spinal BMD than those who used calcitonin (4.5% vs. 0.1%),
but the BMD changes in these two groups at the femoral neck and the total hip were not significant. There were also larger
mean increases in bone markers in the teriparatide group than in the calcitonin group (bone specific alkaline phosphatase
142% vs. 37%; osteocalcin 154% vs. 23%). We conclude that teriparatide has more positive effects on bone formation than salmon
calcitonin, as shown by the larger increments of lumbar spine BMD and bone formation markers, and caused only mild adverse
events and no significant change in liver, kidney or hematological parameters. Compared with the published global results,
teriparatide seems to be equally effective and safe to use in this Asian population. 相似文献
50.
青年人原发性肝癌的治疗与预后分析 总被引:2,自引:0,他引:2
目的:探讨青年人原发性肝癌手术切除率低及术后复发率较高的原因.方法:将1985年1月~2000年1月收治的原发性肝癌173例患者分为青年组(≤35岁)83例和中老年组(≥36岁)90例,对其临床资料、手术切除率、术后复发率及生存率等进行比较分析.结果:青年组原发性肝癌手术切除率、术后1年复发率分别为26.51%(22/83)和68.18%(15/22),术后1、3、5年生存率分别为59.09%(13/22)、22.73%(5/22)和9.09%(2/22).中老年组原发性肝癌手术切除率、术后1年复发率分别为53.33%(48/90)和37.50%(18/48),术后1、3、5年生存率分别为81.25%(39/48)、47.92%(23/48)和39.58%(19/48).青年组各项生存率指标均较中老年组低(P<0.01).结论:青年组原发性肝癌具有肿瘤生长迅速、侵袭力强、门静脉癌栓发生率高、多表现为巨块型及弥漫型等特点,导致手术切除率较低及术后复发率较高. 相似文献